Latest news

  • 18 October 2017

    2017 First-half results Read

  • 12 September 2017

    Sensorion’s Oral SENS-401 Prevented Cisplatin-Induced Hearing Loss By More than 50 Percent in Preclinical Study Read

  • Company

    Sensorion combines world-class, scientific excellence and top-tier execution capabilities to deliver first-in-class therapeutics as a “pure player” focused on debilitating inner ear disorders. Read more

  • Pipeline

    Sensorion has two products in clinical trials, and with our efficient, in-house technology platform, we are well positioned to deliver and expand our pipeline. Read more

  • Investors

     Sensorion is focused on addressing treatment needs for 140 million of patients suffering from debilitating inner ear disorders having limited treatment options. Read more